 Daniel Pollyea
Concepts (471)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 114 | 2025 | 630 | 26.290 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 38 | 2025 | 227 | 10.420 |
Why?
| | Sulfonamides | 33 | 2025 | 513 | 8.470 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 49 | 2025 | 1692 | 7.740 |
Why?
| | Myelodysplastic Syndromes | 29 | 2025 | 135 | 7.110 |
Why?
| | Azacitidine | 23 | 2024 | 140 | 6.470 |
Why?
| | Antineoplastic Agents | 25 | 2025 | 2129 | 3.160 |
Why?
| | Mutation | 36 | 2025 | 3958 | 3.150 |
Why?
| | Isocitrate Dehydrogenase | 13 | 2022 | 59 | 2.940 |
Why?
| | Hematologic Neoplasms | 10 | 2023 | 156 | 2.770 |
Why?
| | Neoplastic Stem Cells | 14 | 2025 | 399 | 2.350 |
Why?
| | Hematopoietic Stem Cell Transplantation | 17 | 2024 | 622 | 2.270 |
Why?
| | Neoplasm, Residual | 7 | 2024 | 133 | 2.270 |
Why?
| | Triazines | 7 | 2021 | 43 | 1.940 |
Why?
| | Aminopyridines | 7 | 2021 | 98 | 1.880 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2025 | 1079 | 1.700 |
Why?
| | Graft vs Host Disease | 9 | 2024 | 252 | 1.690 |
Why?
| | Prognosis | 29 | 2025 | 4030 | 1.540 |
Why?
| | Remission Induction | 15 | 2021 | 288 | 1.510 |
Why?
| | RNA Splicing Factors | 3 | 2020 | 53 | 1.430 |
Why?
| | Aged, 80 and over | 34 | 2025 | 7635 | 1.410 |
Why?
| | Humans | 158 | 2025 | 137585 | 1.370 |
Why?
| | Aged | 61 | 2025 | 23961 | 1.360 |
Why?
| | Phosphoproteins | 3 | 2020 | 338 | 1.230 |
Why?
| | Cytarabine | 8 | 2022 | 61 | 1.230 |
Why?
| | Treatment Outcome | 34 | 2025 | 10811 | 1.110 |
Why?
| | Leukemia | 4 | 2023 | 240 | 1.110 |
Why?
| | Immunotherapy, Adoptive | 3 | 2025 | 327 | 1.010 |
Why?
| | Salvage Therapy | 5 | 2023 | 142 | 1.010 |
Why?
| | Clonal Evolution | 2 | 2017 | 45 | 0.980 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2025 | 7 | 0.970 |
Why?
| | Cord Blood Stem Cell Transplantation | 4 | 2024 | 99 | 0.960 |
Why?
| | Middle Aged | 49 | 2025 | 33479 | 0.910 |
Why?
| | Drug Resistance, Neoplasm | 9 | 2025 | 801 | 0.890 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 73 | 0.880 |
Why?
| | fms-Like Tyrosine Kinase 3 | 4 | 2017 | 48 | 0.880 |
Why?
| | Nuclear Proteins | 5 | 2018 | 712 | 0.870 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 289 | 0.860 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2025 | 203 | 0.860 |
Why?
| | Molecular Targeted Therapy | 7 | 2024 | 411 | 0.830 |
Why?
| | Transplantation Conditioning | 9 | 2024 | 170 | 0.810 |
Why?
| | Carrier Proteins | 3 | 2017 | 771 | 0.810 |
Why?
| | Leukemia, Neutrophilic, Chronic | 3 | 2019 | 5 | 0.800 |
Why?
| | Thrombocytopenia | 2 | 2023 | 200 | 0.770 |
Why?
| | Spliceosomes | 2 | 2020 | 48 | 0.770 |
Why?
| | Dancing | 1 | 2022 | 15 | 0.770 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 4 | 2018 | 233 | 0.740 |
Why?
| | Anemia | 2 | 2020 | 170 | 0.730 |
Why?
| | Enzyme Inhibitors | 5 | 2020 | 840 | 0.730 |
Why?
| | Male | 58 | 2025 | 67762 | 0.720 |
Why?
| | Female | 63 | 2025 | 73304 | 0.700 |
Why?
| | Febrile Neutropenia | 1 | 2020 | 6 | 0.700 |
Why?
| | Adult | 36 | 2025 | 37929 | 0.690 |
Why?
| | Splicing Factor U2AF | 2 | 2023 | 16 | 0.670 |
Why?
| | Receptors, Colony-Stimulating Factor | 2 | 2017 | 7 | 0.640 |
Why?
| | Serine-Arginine Splicing Factors | 2 | 2019 | 22 | 0.640 |
Why?
| | T-Lymphocytes | 2 | 2025 | 1996 | 0.630 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2025 | 122 | 0.630 |
Why?
| | Phenylurea Compounds | 7 | 2020 | 97 | 0.590 |
Why?
| | DNA Methylation | 3 | 2019 | 643 | 0.580 |
Why?
| | Staurosporine | 1 | 2017 | 20 | 0.570 |
Why?
| | Stem Cells | 3 | 2020 | 594 | 0.560 |
Why?
| | Benzimidazoles | 6 | 2020 | 170 | 0.540 |
Why?
| | Protein Kinase Inhibitors | 10 | 2025 | 916 | 0.510 |
Why?
| | Gene Frequency | 2 | 2017 | 521 | 0.510 |
Why?
| | Recurrence | 9 | 2023 | 1060 | 0.490 |
Why?
| | Monocytes | 2 | 2018 | 563 | 0.490 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 6 | 0.490 |
Why?
| | Glycine | 4 | 2021 | 176 | 0.490 |
Why?
| | Leukocytosis | 1 | 2015 | 30 | 0.490 |
Why?
| | Gene Expression | 1 | 2020 | 1502 | 0.480 |
Why?
| | Skin Neoplasms | 1 | 2023 | 855 | 0.470 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 539 | 0.470 |
Why?
| | Signal Transduction | 9 | 2022 | 5079 | 0.460 |
Why?
| | Retrospective Studies | 16 | 2024 | 15657 | 0.450 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 660 | 0.450 |
Why?
| | Precision Medicine | 1 | 2018 | 429 | 0.450 |
Why?
| | Maximum Tolerated Dose | 5 | 2019 | 199 | 0.440 |
Why?
| | Oxidative Phosphorylation | 6 | 2024 | 193 | 0.440 |
Why?
| | Pyridines | 5 | 2023 | 506 | 0.440 |
Why?
| | Computational Biology | 1 | 2019 | 644 | 0.440 |
Why?
| | Patient Safety | 1 | 2018 | 314 | 0.440 |
Why?
| | Medical Oncology | 4 | 2023 | 289 | 0.440 |
Why?
| | Induction Chemotherapy | 3 | 2024 | 76 | 0.420 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2024 | 50 | 0.420 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2024 | 106 | 0.420 |
Why?
| | Hematopoiesis | 4 | 2020 | 192 | 0.420 |
Why?
| | Neoplasm Proteins | 4 | 2022 | 434 | 0.420 |
Why?
| | Pyrazoles | 1 | 2017 | 423 | 0.410 |
Why?
| | Apoptosis | 4 | 2018 | 2553 | 0.410 |
Why?
| | Immunity, Innate | 1 | 2019 | 828 | 0.400 |
Why?
| | Germ-Line Mutation | 3 | 2022 | 172 | 0.400 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 2057 | 0.390 |
Why?
| | Leukemia, Myeloid | 1 | 2012 | 45 | 0.390 |
Why?
| | Glutarates | 1 | 2012 | 10 | 0.390 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 2 | 2018 | 32 | 0.380 |
Why?
| | Biomarkers, Tumor | 5 | 2025 | 1276 | 0.370 |
Why?
| | Survival Rate | 11 | 2025 | 1972 | 0.370 |
Why?
| | RNA Splicing | 4 | 2023 | 269 | 0.360 |
Why?
| | Neutrophils | 2 | 2023 | 1238 | 0.360 |
Why?
| | Follow-Up Studies | 8 | 2020 | 5131 | 0.350 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 365 | 0.350 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2023 | 804 | 0.350 |
Why?
| | United States Food and Drug Administration | 2 | 2022 | 208 | 0.350 |
Why?
| | Young Adult | 15 | 2024 | 13209 | 0.340 |
Why?
| | Aldehyde Dehydrogenase | 3 | 2017 | 100 | 0.340 |
Why?
| | Neoplasms | 4 | 2018 | 2671 | 0.330 |
Why?
| | Leukocyte Count | 2 | 2024 | 329 | 0.330 |
Why?
| | Rhipicephalus sanguineus | 1 | 2009 | 1 | 0.330 |
Why?
| | Triatoma | 1 | 2009 | 7 | 0.330 |
Why?
| | Insect Bites and Stings | 1 | 2009 | 12 | 0.330 |
Why?
| | Wasps | 1 | 2009 | 15 | 0.320 |
Why?
| | Syncope | 1 | 2009 | 52 | 0.310 |
Why?
| | Electron Transport Complex II | 2 | 2019 | 26 | 0.300 |
Why?
| | Cytokines | 4 | 2020 | 2085 | 0.300 |
Why?
| | Kaplan-Meier Estimate | 5 | 2020 | 889 | 0.300 |
Why?
| | Mutant Proteins | 2 | 2019 | 103 | 0.300 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 148 | 0.300 |
Why?
| | Cell Self Renewal | 2 | 2019 | 56 | 0.290 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 648 | 0.290 |
Why?
| | Administration, Oral | 4 | 2018 | 816 | 0.290 |
Why?
| | Risk Assessment | 5 | 2024 | 3457 | 0.290 |
Why?
| | Acute Disease | 3 | 2023 | 1007 | 0.290 |
Why?
| | Anaphylaxis | 1 | 2009 | 105 | 0.290 |
Why?
| | Bone Marrow | 4 | 2017 | 286 | 0.290 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2024 | 1477 | 0.280 |
Why?
| | Transplantation, Homologous | 6 | 2022 | 416 | 0.280 |
Why?
| | Survival Analysis | 6 | 2020 | 1325 | 0.280 |
Why?
| | Gene Expression Regulation, Leukemic | 3 | 2016 | 56 | 0.270 |
Why?
| | Drug Administration Schedule | 4 | 2020 | 786 | 0.270 |
Why?
| | Disease-Free Survival | 5 | 2022 | 686 | 0.270 |
Why?
| | Thrombocythemia, Essential | 2 | 2016 | 7 | 0.250 |
Why?
| | Polycythemia Vera | 2 | 2016 | 12 | 0.250 |
Why?
| | Mitochondria | 3 | 2024 | 948 | 0.250 |
Why?
| | Primary Myelofibrosis | 2 | 2016 | 10 | 0.250 |
Why?
| | Animals | 26 | 2025 | 36940 | 0.240 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 1050 | 0.240 |
Why?
| | Cytogenetic Analysis | 2 | 2022 | 33 | 0.240 |
Why?
| | Hematopoietic Stem Cells | 3 | 2022 | 406 | 0.240 |
Why?
| | Influenza Vaccines | 1 | 2010 | 539 | 0.230 |
Why?
| | Phenotype | 3 | 2025 | 3196 | 0.230 |
Why?
| | DEAD-box RNA Helicases | 2 | 2015 | 76 | 0.230 |
Why?
| | Mice | 18 | 2025 | 17787 | 0.230 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 22 | 0.220 |
Why?
| | Allografts | 2 | 2021 | 146 | 0.210 |
Why?
| | Stem Cell Transplantation | 3 | 2023 | 176 | 0.210 |
Why?
| | Influenza, Human | 1 | 2010 | 622 | 0.210 |
Why?
| | Azetidines | 1 | 2024 | 43 | 0.210 |
Why?
| | Finland | 1 | 2023 | 85 | 0.210 |
Why?
| | DNA Mutational Analysis | 4 | 2019 | 399 | 0.200 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1430 | 0.200 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 1502 | 0.200 |
Why?
| | Drug Therapy, Combination | 4 | 2022 | 1066 | 0.200 |
Why?
| | Down-Regulation | 1 | 2025 | 657 | 0.200 |
Why?
| | Antibodies, Neoplasm | 3 | 2007 | 34 | 0.200 |
Why?
| | Disease Management | 4 | 2021 | 628 | 0.200 |
Why?
| | Uncertainty | 1 | 2023 | 128 | 0.200 |
Why?
| | RNA, Messenger | 1 | 2010 | 2833 | 0.190 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 17 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2022 | 139 | 0.190 |
Why?
| | Hematology | 1 | 2022 | 20 | 0.190 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2023 | 87 | 0.190 |
Why?
| | Myeloproliferative Disorders | 1 | 2022 | 27 | 0.190 |
Why?
| | Piperidines | 1 | 2024 | 206 | 0.190 |
Why?
| | Thalidomide | 2 | 2012 | 40 | 0.190 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.190 |
Why?
| | Succinate Dehydrogenase | 2 | 2019 | 50 | 0.190 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 48 | 0.180 |
Why?
| | Disease Progression | 3 | 2023 | 2757 | 0.180 |
Why?
| | Receptors, Mitogen | 1 | 2021 | 9 | 0.180 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1062 | 0.180 |
Why?
| | Lipids | 1 | 2025 | 672 | 0.170 |
Why?
| | Lectins, C-Type | 1 | 2021 | 67 | 0.170 |
Why?
| | Blood Cell Count | 1 | 2020 | 55 | 0.170 |
Why?
| | Erythroblasts | 1 | 2020 | 19 | 0.170 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 327 | 0.170 |
Why?
| | Lipase | 1 | 2020 | 69 | 0.170 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 206 | 0.160 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 126 | 0.160 |
Why?
| | Inflammation Mediators | 2 | 2020 | 513 | 0.160 |
Why?
| | Tumor Lysis Syndrome | 1 | 2019 | 8 | 0.160 |
Why?
| | Dendritic Cells | 1 | 2023 | 483 | 0.160 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2021 | 137 | 0.160 |
Why?
| | Immunoconjugates | 1 | 2021 | 114 | 0.160 |
Why?
| | Leukopoiesis | 1 | 2019 | 11 | 0.160 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 39 | 0.150 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 17 | 0.150 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2019 | 26 | 0.150 |
Why?
| | Fatty Acids | 2 | 2020 | 443 | 0.150 |
Why?
| | K562 Cells | 1 | 2019 | 89 | 0.150 |
Why?
| | RAW 264.7 Cells | 1 | 2019 | 50 | 0.150 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 10 | 0.150 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 16 | 0.150 |
Why?
| | Age Factors | 5 | 2022 | 3295 | 0.150 |
Why?
| | Mycoses | 1 | 2019 | 79 | 0.150 |
Why?
| | Antibodies | 1 | 2021 | 410 | 0.150 |
Why?
| | Genetic Testing | 2 | 2019 | 460 | 0.150 |
Why?
| | Hematologic Diseases | 1 | 2019 | 62 | 0.150 |
Why?
| | Genomics | 3 | 2019 | 795 | 0.150 |
Why?
| | Amino Acids | 2 | 2020 | 497 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 528 | 0.150 |
Why?
| | Mitochondrial Proteins | 2 | 2018 | 257 | 0.150 |
Why?
| | Antibiotic Prophylaxis | 1 | 2019 | 119 | 0.150 |
Why?
| | United States | 5 | 2023 | 14841 | 0.150 |
Why?
| | Thiotepa | 1 | 2018 | 20 | 0.150 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 94 | 0.150 |
Why?
| | Calcium | 1 | 2024 | 1199 | 0.150 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3412 | 0.150 |
Why?
| | Trees | 1 | 2018 | 71 | 0.140 |
Why?
| | Lymphoma | 2 | 2017 | 208 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 204 | 0.140 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 69 | 0.140 |
Why?
| | HLA-DR Antigens | 1 | 2018 | 228 | 0.130 |
Why?
| | Confidence Intervals | 1 | 2018 | 329 | 0.130 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 45 | 0.130 |
Why?
| | Hematinics | 1 | 2017 | 22 | 0.130 |
Why?
| | Infusions, Intravenous | 1 | 2018 | 413 | 0.130 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2018 | 197 | 0.130 |
Why?
| | Hedgehog Proteins | 1 | 2018 | 195 | 0.130 |
Why?
| | Periodicals as Topic | 1 | 2019 | 211 | 0.130 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 66 | 0.130 |
Why?
| | Unrelated Donors | 1 | 2016 | 39 | 0.130 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 60 | 0.130 |
Why?
| | Cohort Studies | 5 | 2022 | 5742 | 0.130 |
Why?
| | Genome, Human | 1 | 2018 | 425 | 0.120 |
Why?
| | Pyrimidines | 2 | 2017 | 470 | 0.120 |
Why?
| | Nitriles | 1 | 2017 | 172 | 0.120 |
Why?
| | Geriatric Assessment | 1 | 2018 | 224 | 0.120 |
Why?
| | Energy Metabolism | 2 | 2019 | 922 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 2016 | 59 | 0.120 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 93 | 0.120 |
Why?
| | Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 14 | 0.120 |
Why?
| | Mice, Inbred NOD | 4 | 2019 | 601 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 2 | 2022 | 2426 | 0.120 |
Why?
| | Methyltransferases | 1 | 2016 | 78 | 0.120 |
Why?
| | Lipopolysaccharides | 1 | 2019 | 886 | 0.120 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 70 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 249 | 0.120 |
Why?
| | Biomarkers | 3 | 2022 | 4149 | 0.120 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.120 |
Why?
| | Hemoglobins | 2 | 2018 | 353 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2023 | 1069 | 0.120 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 156 | 0.110 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 19 | 0.110 |
Why?
| | Adolescent | 7 | 2024 | 21513 | 0.110 |
Why?
| | Homeostasis | 1 | 2018 | 621 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 317 | 0.110 |
Why?
| | Cell Survival | 4 | 2022 | 1120 | 0.110 |
Why?
| | Necrosis | 1 | 2015 | 246 | 0.110 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 72 | 0.110 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 136 | 0.110 |
Why?
| | Cells, Cultured | 5 | 2019 | 4193 | 0.110 |
Why?
| | Vidarabine | 2 | 2018 | 33 | 0.110 |
Why?
| | Harringtonines | 1 | 2013 | 2 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2031 | 0.100 |
Why?
| | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2013 | 1 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 327 | 0.100 |
Why?
| | Alemtuzumab | 3 | 2007 | 15 | 0.100 |
Why?
| | Glucose | 1 | 2018 | 1020 | 0.100 |
Why?
| | Registries | 2 | 2023 | 2035 | 0.100 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1774 | 0.100 |
Why?
| | Interleukin-1 | 1 | 2017 | 965 | 0.100 |
Why?
| | Pyridazines | 1 | 2013 | 56 | 0.100 |
Why?
| | Carbon Monoxide | 1 | 2013 | 81 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1396 | 0.100 |
Why?
| | Nausea | 1 | 2012 | 111 | 0.100 |
Why?
| | 5-Methylcytosine | 1 | 2012 | 22 | 0.100 |
Why?
| | Vomiting | 1 | 2012 | 130 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1129 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1943 | 0.090 |
Why?
| | Imidazoles | 1 | 2013 | 238 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2018 | 1164 | 0.090 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 2 | 2023 | 31 | 0.090 |
Why?
| | Incidence | 2 | 2016 | 2804 | 0.090 |
Why?
| | Amino Acid Sequence | 2 | 2015 | 2139 | 0.090 |
Why?
| | Dioxygenases | 1 | 2010 | 26 | 0.090 |
Why?
| | Sesquiterpenes | 2 | 2016 | 55 | 0.080 |
Why?
| | Fatigue | 1 | 2012 | 329 | 0.080 |
Why?
| | Length of Stay | 1 | 2016 | 1215 | 0.080 |
Why?
| | Oxidants | 1 | 2011 | 111 | 0.080 |
Why?
| | Software | 1 | 2015 | 665 | 0.080 |
Why?
| | GTP-Binding Proteins | 1 | 2011 | 161 | 0.080 |
Why?
| | Ethanol | 1 | 2015 | 608 | 0.080 |
Why?
| | Wasp Venoms | 1 | 2009 | 4 | 0.080 |
Why?
| | Chronic Disease | 1 | 2016 | 1793 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2018 | 1208 | 0.080 |
Why?
| | Blast Crisis | 2 | 2025 | 33 | 0.080 |
Why?
| | Protein Multimerization | 1 | 2011 | 192 | 0.080 |
Why?
| | Injections, Subcutaneous | 1 | 2009 | 157 | 0.080 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 328 | 0.080 |
Why?
| | Epinephrine | 1 | 2009 | 139 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2023 | 2167 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 226 | 0.070 |
Why?
| | Emergencies | 1 | 2009 | 164 | 0.070 |
Why?
| | Immunization Schedule | 1 | 2010 | 197 | 0.070 |
Why?
| | RNA, Small Interfering | 3 | 2016 | 622 | 0.070 |
Why?
| | Melphalan | 1 | 2007 | 35 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2837 | 0.070 |
Why?
| | Blood Transfusion | 2 | 2020 | 325 | 0.070 |
Why?
| | Transplantation Chimera | 1 | 2007 | 54 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2022 | 955 | 0.070 |
Why?
| | Karnofsky Performance Status | 1 | 2006 | 38 | 0.060 |
Why?
| | HEK293 Cells | 2 | 2019 | 730 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 5757 | 0.060 |
Why?
| | Receptors, Thrombopoietin | 2 | 2016 | 6 | 0.060 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2014 | 434 | 0.060 |
Why?
| | Calreticulin | 2 | 2016 | 28 | 0.060 |
Why?
| | Janus Kinase 2 | 2 | 2016 | 32 | 0.060 |
Why?
| | Ganciclovir | 1 | 2006 | 53 | 0.060 |
Why?
| | Exome | 2 | 2018 | 231 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.060 |
Why?
| | Valine | 1 | 2006 | 82 | 0.060 |
Why?
| | Acyclovir | 1 | 2006 | 101 | 0.060 |
Why?
| | Philadelphia Chromosome | 2 | 2016 | 18 | 0.060 |
Why?
| | Cell Proliferation | 3 | 2020 | 2475 | 0.060 |
Why?
| | Risk Factors | 3 | 2014 | 10388 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 286 | 0.060 |
Why?
| | Janus Kinases | 2 | 2015 | 15 | 0.050 |
Why?
| | Pedigree | 2 | 2015 | 514 | 0.050 |
Why?
| | Oxidation-Reduction | 2 | 2019 | 1060 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 2006 | 192 | 0.050 |
Why?
| | Diamines | 1 | 2023 | 4 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 88 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 131 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2016 | 872 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2015 | 2253 | 0.050 |
Why?
| | Flow Cytometry | 2 | 2018 | 1178 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2004 | 229 | 0.050 |
Why?
| | Neutropenia | 1 | 2022 | 146 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1587 | 0.050 |
Why?
| | Drug Interactions | 2 | 2013 | 410 | 0.050 |
Why?
| | Early Termination of Clinical Trials | 1 | 2021 | 17 | 0.040 |
Why?
| | Quinuclidines | 1 | 2020 | 9 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2020 | 76 | 0.040 |
Why?
| | Machine Learning | 1 | 2025 | 493 | 0.040 |
Why?
| | Hyperbilirubinemia | 1 | 2020 | 13 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2022 | 385 | 0.040 |
Why?
| | Niacinamide | 1 | 2020 | 82 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2006 | 744 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1266 | 0.040 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 118 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 56 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 310 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.040 |
Why?
| | Daunorubicin | 1 | 2018 | 26 | 0.040 |
Why?
| | Consolidation Chemotherapy | 1 | 2018 | 10 | 0.040 |
Why?
| | Mice, Nude | 2 | 2015 | 698 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 35 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 218 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 22 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.040 |
Why?
| | Iron | 1 | 2020 | 313 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2016 | 3015 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2018 | 121 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 191 | 0.040 |
Why?
| | Cause of Death | 1 | 2020 | 434 | 0.040 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 78 | 0.040 |
Why?
| | Fetal Blood | 1 | 2020 | 327 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 322 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 190 | 0.030 |
Why?
| | HLA Antigens | 1 | 2019 | 240 | 0.030 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 15 | 0.030 |
Why?
| | Cell Count | 1 | 2018 | 324 | 0.030 |
Why?
| | Biological Transport | 1 | 2018 | 418 | 0.030 |
Why?
| | Child | 2 | 2024 | 21935 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4295 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2017 | 34 | 0.030 |
Why?
| | Glutathione | 1 | 2019 | 356 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1236 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2017 | 29 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 247 | 0.030 |
Why?
| | Oxides | 1 | 2017 | 46 | 0.030 |
Why?
| | Arsenicals | 1 | 2017 | 30 | 0.030 |
Why?
| | Glycolysis | 1 | 2018 | 321 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 33 | 0.030 |
Why?
| | NADP | 1 | 2016 | 49 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2019 | 491 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 138 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 35 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2017 | 247 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 53 | 0.030 |
Why?
| | Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2016 | 10 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 674 | 0.030 |
Why?
| | Drug Combinations | 1 | 2017 | 343 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 216 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 622 | 0.030 |
Why?
| | Sample Size | 1 | 2016 | 125 | 0.030 |
Why?
| | Kinetics | 1 | 2019 | 1670 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 971 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2017 | 283 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 452 | 0.030 |
Why?
| | Isoenzymes | 1 | 2016 | 304 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 294 | 0.030 |
Why?
| | Splenomegaly | 1 | 2015 | 15 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2023 | 986 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2017 | 366 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 350 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2017 | 382 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Hydroxyurea | 1 | 2015 | 35 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2018 | 427 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 518 | 0.030 |
Why?
| | Comorbidity | 2 | 2013 | 1622 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1483 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 390 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 372 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 72 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2014 | 79 | 0.030 |
Why?
| | Sirolimus | 1 | 2016 | 276 | 0.030 |
Why?
| | Immunologic Factors | 1 | 2017 | 236 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 1991 | 0.030 |
Why?
| | Quality of Life | 2 | 2016 | 2892 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 385 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 202 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 54 | 0.030 |
Why?
| | Age of Onset | 1 | 2015 | 518 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2015 | 570 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 123 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2014 | 59 | 0.030 |
Why?
| | Leukemia, Lymphoid | 1 | 2013 | 27 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 843 | 0.030 |
Why?
| | Trans-Activators | 1 | 2016 | 398 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 1139 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 382 | 0.030 |
Why?
| | Cyclosporine | 1 | 2014 | 268 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 75 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 469 | 0.020 |
Why?
| | Phosphorylation | 1 | 2017 | 1759 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1272 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2189 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2016 | 506 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 591 | 0.020 |
Why?
| | Leupeptins | 1 | 2011 | 10 | 0.020 |
Why?
| | Thrombosis | 1 | 2015 | 371 | 0.020 |
Why?
| | HL-60 Cells | 1 | 2011 | 34 | 0.020 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2011 | 49 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 600 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 46 | 0.020 |
Why?
| | Mitoxantrone | 1 | 2010 | 14 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2011 | 88 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1916 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 2900 | 0.020 |
Why?
| | Etoposide | 1 | 2010 | 158 | 0.020 |
Why?
| | Acetylcysteine | 1 | 2011 | 145 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2011 | 176 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 375 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 156 | 0.020 |
Why?
| | Prospective Studies | 2 | 2016 | 7604 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2734 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1783 | 0.020 |
Why?
| | Treatment Failure | 1 | 2010 | 356 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2409 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2011 | 422 | 0.020 |
Why?
| | Nitroimidazoles | 1 | 2004 | 13 | 0.010 |
Why?
| | Cyclohexanes | 1 | 2004 | 21 | 0.010 |
Why?
| | Fluorescein | 1 | 2004 | 25 | 0.010 |
Why?
| | In Situ Nick-End Labeling | 1 | 2004 | 124 | 0.010 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2004 | 43 | 0.010 |
Why?
| | Lectins | 1 | 2004 | 49 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 2004 | 257 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2004 | 316 | 0.010 |
Why?
| | Microcirculation | 1 | 2004 | 149 | 0.010 |
Why?
| | Capillaries | 1 | 2004 | 108 | 0.010 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2004 | 127 | 0.010 |
Why?
| | Angiography | 1 | 2004 | 207 | 0.010 |
Why?
| | Wilms Tumor | 1 | 2004 | 86 | 0.010 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 301 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 545 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1738 | 0.010 |
Why?
| | Hypoxia | 1 | 2004 | 1112 | 0.010 |
Why?
|
|
Pollyea's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|